Nexus BioPharma, Inc. (the“Company”)prepared an investor presentation to be used in certain investor meetings, beginning May 17, 2017. The presentation included a power point presentation in the form attached hereto as Exhibit 99.1.

This information is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934 or the Securities Act of 1933 only if and to the extent such subsequent filing specifically references the information incorporated by reference herein.

All statements in this report that do not directly and exclusively relate to historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements represent the Company’s intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factorsmany ofwhich are outside the Company’s control. These factors could cause actual results to differ materially from such forward-looking statements. For a written description of these factors, see the section titled “Risk Factors” in the Company’s Form 10-K for the fiscal year ended February 28, 2016 and any updating information in subsequent SEC filings.The Company disclaims any intention or obligation to update these forward-looking statements whether as a result of subsequent event or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

See Exhibit Index.

About NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS)

Nexus Biopharma, Inc., formerly Plata Resources, Inc., is engaged in developing a weight loss drug that activates the 5′ adenosine monophosphate-activated protein kinase (AMPK) metabolic pathway. The Company is developing a treatment for obesity. It has worked for the virtual screening, assay development and optimization, compound selection and screening, and active-to-hit work to support hit identification of inhibitors of Fyn kinase. It is also focused on developing a drug for the blood chemistry improvements for type 2 diabetes. The Company has completed pre-clinical trials of the pharmaceutical activation of AMPK metabolic pathway. The Company focuses on advancing these to pre-Investigational New Drug (IND) trials in preparation for the United States Food and Drug Administration (FDA) human trials of a drug.

NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS) Recent Trading Information

NEXUS BIOPHARMA, INC. (OTCMKTS:NEXS) closed its last trading session up +0.010 at 0.460 with 1,415,616 shares trading hands.